These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 15054158

  • 1. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P, Peris P, Guañabens N, Byrjalsen I, Alvarez L, Solberg H, Cloos PA.
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [Abstract] [Full Text] [Related]

  • 5. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P, Alvarez L, Vidal S, Martínez MA, Monegal A, Guañabens N.
    Clin Exp Rheumatol; 2007 Apr; 25(2):206-10. PubMed ID: 17543143
    [Abstract] [Full Text] [Related]

  • 6. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L, Guañabens N, Peris P, Vidal S, Ros I, Monegal A, Bedini JL, Deulofeu R, Pons F, Muñoz-Gomez J, Ballesta AM.
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.
    Peris P, Alvarez L, Vidal S, Kasper D, Leeming DJ, Monegal A, Angeles Martínez M, Pons F, Guañabens N.
    Calcif Tissue Int; 2006 Jul; 79(1):22-6. PubMed ID: 16868670
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos NK, Economopoulos T, Raptis SA.
    Anticancer Res; 2005 Jul; 25(2B):1457-63. PubMed ID: 15865105
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone.
    Reginster JY, Treves R, Renier JC, Amor B, Sany J, Ethgen D, Picot C, Franchimont P.
    J Bone Miner Res; 1994 May; 9(5):615-9. PubMed ID: 8053389
    [Abstract] [Full Text] [Related]

  • 17. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C, Rapado A, Díaz Diego EM, Díaz Martín MA, Aguirre C, López Gavilanes E, Díaz Curiel M.
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [Abstract] [Full Text] [Related]

  • 18. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
    Papapoulos SE, Frölich M.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.